These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
431 related items for PubMed ID: 7634181
1. Clinical values of CA19-9, CA125 and CEA in malignant obstructive jaundice. Ng WW, Tong KJ, Tam TN, Lee SD. Zhonghua Yi Xue Za Zhi (Taipei); 1995 Jun; 55(6):438-46. PubMed ID: 7634181 [Abstract] [Full Text] [Related]
4. CA19-9 serum levels in obstructive jaundice: clinical value in benign and malignant conditions. Marrelli D, Caruso S, Pedrazzani C, Neri A, Fernandes E, Marini M, Pinto E, Roviello F. Am J Surg; 2009 Sep; 198(3):333-9. PubMed ID: 19375064 [Abstract] [Full Text] [Related]
5. CA72-4 combined with CEA, CA125 and CAl9-9 improves the sensitivity for the early diagnosis of gastric cancer. Yang AP, Liu J, Lei HY, Zhang QW, Zhao L, Yang GH. Clin Chim Acta; 2014 Nov 01; 437():183-6. PubMed ID: 25086284 [Abstract] [Full Text] [Related]
8. Postoperative serum CA19-9, CEA and CA125 predicts the response to adjuvant chemoradiotherapy following radical resection in pancreatic adenocarcinoma. Xu HX, Li S, Wu CT, Qi ZH, Wang WQ, Jin W, Gao HL, Zhang SR, Xu JZ, Liu C, Long J, Xu J, Ni QX, Yu XJ, Liu L. Pancreatology; 2018 Sep 01; 18(6):671-677. PubMed ID: 30153903 [Abstract] [Full Text] [Related]
11. The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer. Ni XG, Bai XF, Mao YL, Shao YF, Wu JX, Shan Y, Wang CF, Wang J, Tian YT, Liu Q, Xu DK, Zhao P. Eur J Surg Oncol; 2005 Mar 01; 31(2):164-9. PubMed ID: 15698733 [Abstract] [Full Text] [Related]
19. Evaluation of Serum CEA, CA19-9, CA72-4, CA125 and Ferritin as Diagnostic Markers and Factors of Clinical Parameters for Colorectal Cancer. Gao Y, Wang J, Zhou Y, Sheng S, Qian SY, Huo X. Sci Rep; 2018 Feb 09; 8(1):2732. PubMed ID: 29426902 [Abstract] [Full Text] [Related]
20. Significance of serum and bile tumor markers in the diagnostic approach of patients with malignant pancreatobiliary disease. Natsios A, Vezakis A, Kaparos G, Fragulidis G, Karakostas N, Kouskouni E, Logothetis E, Polydorou A. J BUON; 2015 Feb 09; 20(4):1030-6. PubMed ID: 26416052 [Abstract] [Full Text] [Related] Page: [Next] [New Search]